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Abstract
Enzymatic inactivation of Rho-family GTPases by the glucosyltransferase domain of Clostri-
dioides difficile Toxin B (TcdB) gives rise to various pathogenic effects in cells that are clas-
sically thought to be responsible for the disease symptoms associated with C. difficile
infection (CDI). Recent in vitro studies have shown that TcdB can, under certain circum-
stances, induce cellular toxicities that are independent of glucosyltransferase (GT) activity,
calling into question the precise role of GT activity. Here, to establish the importance of GT
activity in CDI disease pathogenesis, we generated the first described mutant strain of C.
difficile producing glucosyltransferase-defective (GT-defective) toxin. Using allelic
exchange (AE) technology, we first deleted tcdA in C. difficile 630Δerm and subsequently
introduced a deactivating D270N substitution in the GT domain of TcdB. To examine the
role of GT activity in vivo, we tested each strain in two different animal models of CDI patho-
genesis. In the non-lethal murine model of infection, the GT-defective mutant induced mini-
mal pathology in host tissues as compared to the profound caecal inflammation seen in the
wild-type and 630ΔermΔtcdA (ΔtcdA) strains. In the more sensitive hamster model of CDI,
whereas hamsters in the wild-type or ΔtcdA groups succumbed to fulminant infection within
4 days, all hamsters infected with the GT-defective mutant survived the 10-day infection
period without primary symptoms of CDI or evidence of caecal inflammation. These data
demonstrate that GT activity is indispensable for disease pathogenesis and reaffirm its cen-
tral role in disease and its importance as a therapeutic target for small-molecule inhibition.
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Author summary
Novel non-antibiotic therapies are required for the treatment of Clostridioides difficile
infection (CDI). An emerging class of promising therapeutics for CDI are antivirulence
agents that block the actions of C. difficile Toxin B (TcdB), the primary determinant of vir-
ulence. In order to develop such treatments, molecular targets and mechanisms must be
identified and validated. Historically the glucosyltransferase domain (GTD) represented
an ideal target owing to its perceived importance for disease pathogenesis. However, stud-
ies capitalizing on recent advances in recombinant TcdB production have unveiled GTD-
independent mechanisms of toxicity when applied at high concentrations in vitro, thus
questioning the role of the GTD. Here we generate the first-reported mutant strain of C.
difficile expressing glucosyltransferase-defective TcdB. Application thereof demonstrates
that the GTD is essential for disease in mice and hamsters, thus reoffering the GTD as an
ideal candidate for small-molecule inhibitor (SMI) development.
Introduction
Clostridioides difficile (previously known as Clostridium difficile [1]) is the leading cause of nos-
ocomial diarrhea in the developed world [2]. The main virulence factors responsible for the
onset of symptoms during C. difficile infection (CDI), including diarrhea and pseudomembra-
nous colitis, are the monoglucosyltransferases Toxin A (TcdA; 308kDa) and Toxin B (TcdB;
270 kDa) [3]. The application of tcdA and tcdB-null mutant strains to in vivo models, coupled
with the frequent isolation of clinical isolates producing only TcdB, has consolidated the
notion that–though TcdA can contribute to disease severity–TcdB represents the primary vir-
ulence determinant for CDI [4–6]. TcdB is therefore the primary target for the development of
novel toxin-targeted therapeutics, including monoclonal antibodies and small-molecule inhib-
itors (SMIs).
TcdB is a single polypeptide cytotoxin composed of four distinct domains: a receptor-bind-
ing domain (RBD), a translocation domain (TD), an autoprocessing domain (APD), and a glu-
cosyltransferase domain (GTD). TcdB is endocytosed into endosomes following receptor
binding to one of three defined receptors: chondroitin sulfate proteoglycan 4 (CSPG4), Nectin
3 and frizzled protein (FZD1, 2 and 7) at least in part due to interaction with the RBD [7–9].
Thereafter, vesicular acidification leads to a conformational change and protein unfurling,
ascribed to the hydrophobic region of the TD, permitting membrane insertion and the forma-
tion of an endosomal pore, through which the GTD and APD translocate into the cytosol [10].
Cytosolic inositol hexakisphosphate (InsP6) acts as an allosteric activator to initiate the cyste-
ine-protease activity of the APD, which cleaves the GTD, leading to its release into the cytosol
[11]. The GTD then glucosylates Rho-family GTPases leading to the classical phenotype of
rapid actin depolymerization, loss of structural integrity, cell rounding and apoptosis of the
colonic epithelium [12].
Over the past decade, significant efforts have been made to characterize the contribution of
the GTD to disease pathogenesis through the generation of recombinant TcdB defective in glu-
cosyltransferase activity (GT-defective). These studies have unveiled novel GT-independent
mechanisms of toxicity for TcdB. Rapid necrotic cell death was observed independent of the
GTD when GT-defective TcdB was applied in vitro at�1nM [13]. In the same study, an active
GTD domain was required to induce the classical cytopathic effect at concentrations of
<10pM. The necrotic mechanism was later characterized to be dependent on the host
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NADPH oxidase complex [14]. Thereafter, a second GT-independent mechanism of cell death
was discovered to occur through a pyknotic mechanism [15]. In a similar fashion to the afore-
mentioned necrotic mechanism, the pyknotic pathway was restricted to high concentrations
of TcdB. Finally, two studies investigating TcdB-induced inflammasome activation, using
wild-type TcdB and GT-defective TcdB, yielded opposing conclusions on the dependence of
GT activity on inflammasome activation [16, 17]. Such discoveries question the contribution
of the GTD to the pathogenesis of CDI and divert focus for SMI development away from the
GTD. Ultimately, in vivo substantiation of the in vitro discoveries is needed to clarify the
importance of GT activity in a natural disease setting. Previous attempts have been made to
correlate the relevance of the GT-independent mechanisms of TcdB to infection. Therein, GT-
defective TcdB was injected into mice [18], and in parallel, mice were infected with a surrogate
Bacillus megaterium host strain, engineered to secrete GT-defective TcdB [19]. In neither
instance was a GT-independent effect of virulence observed. These experiments question the
relevance of the GT-independent mechanisms of TcdB-induced toxicity to infection, but hith-
erto, no study has been conducted with a strain of C. difficile engineered to produce full-length
GT-defective toxin.
This study sought to clarify the role of the GTD to disease pathogenesis in vivo through the
generation of a mutant strain of C. difficile devoid of GT-activity and its application to murine
and hamster models of infection.
Results and discussion
Mutant strain authentication and in vitro characterization
In an attempt to reconcile and clarify the role of the GTD to the pathogenesis of CDI, we
applied allelic-exchange technology to delete the entire 8133bp tcdA gene from the chromo-
some of C. difficile 630Δerm [20], as described in materials and methods. Successful deletion
was observed by the presence of a circa 2.7kb product following PCR with diagnostic primers
flanking tcdA (Fig 1A). An additional PCR was conducted using internal primers annealing
within tcdA to ensure the absence of contaminating wild-type sub-populations (Fig 1B). The
selected mutant, designated 630ΔermΔpyrEΔtcdA possessed the 2.7Kb deletion fragment and
lacked the circa 500bp internal fragment following both PCR reactions (Fig 1A and 1B). The
deletion was confirmed to be as intended through Sanger sequencing of the resultant ampli-
con. Deletion of tcdA should permit the study of TcdB without the need to consider the contri-
bution of TcdA-mediated virulence. Using the same technology, the trinucleotide gac
encoding Asp 270 in tcdB was mutated to aat to encode Asn ensuing an Asp270Asn (D270N)
substitution. TcdB D270N was previously shown to be the most defective variant for glucosyl-
transferase activity in vitro, and was fully capable of inducing the necrotic mechanism of cell
death [13]. PCR with flanking primers (Fig 1C) followed by Sanger sequencing of the ampli-
con and sequence alignment using the Benchling bioinformatics platform, revealed that the
gac-aat substitution had taken place as intended (Fig 1D). Finally, the pyrE allele was repaired
in both strains exactly as described previously [21]. To probe for unintended polymorphisms
arising as a consequence of the mutagenesis procedure, gDNA was extracted from each strain
and analyzed by next generation sequencing (NGS). No unintended nucleotide variations
were detected for the two mutant strains compared with the wild-type parental. Sequencing
reads were deposited to the NCBI Sequencing Read Archive [22] under accession number
PRJNA623295.
Before proceeding with the animal experiments, it was first necessary to phenotype the
mutants generated herein. The production of TcdA and TcdB was assessed by Western blot on
48h filter-sterilized supernatants of the wild-type and mutant strains. Neither the tcdA-
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Fig 1. Development and authentication of a mutant strain producing GTD-defective TcdB. a) Gel image following PCR of the tcdA gene using the flanking primers
tcdA diag F/tcdA diag R. The presence of a circa 2.7kb band indicates successful gene deletion. b) Gel image following PCR of the tcdA gene using the internal primers
tcdA int F/tcdA int R. The absence of a 500bp product indicates successful gene deletion. c) Gel image following PCR of the GTD of tcdB using GTD diag F/R primers.
Strain labels: C. difficile 630Δerm (WT); C. difficile 630ΔermΔtcdA (tcdA); C. difficile 630ΔermΔtcdA GTD::D270N (GTD). d) Sequence alignment of the GTD region of
tcdB for C. difficile 630ΔermΔtcdA GTD::D270N with the wild-type reference sequence of 630Δerm. The desired gac-aat substitution is highlighted in a red box. e)
Western blot detection for TcdA and TcdB for the wild-type, ΔtcdA and GTD-D270N strains including Poncaeu stains to validate even protein loading. f) 24h
automated growth curve of the wild-type, ΔtcdA and GTD-D270N strains.
https://doi.org/10.1371/journal.ppat.1008852.g001
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deletion strain nor the GT-defective mutant were capable of producing TcdA, as intended (Fig
1E). In a similar fashion, neither strain was affected for the production of TcdB (Fig 1E). Pon-
ceau staining demonstrated adequate and equal protein loading. The strains were then assessed
for their growth capabilities through an automated 24h growth curve. No growth defects were
observed for either mutant when compared with the wild-type parental (Fig 1F).
Glucosyltransferase activity is required for disease pathogenesis in a
murine model
Having generated the requisite mutants, we next investigated their effects in a non-lethal
mouse model of CDI. This model mimics human disease in that gastrointestinal (GI) dysbiosis
is first induced with antibiotics, the inciting risk factor in a majority of human infections. Fur-
ther, a majority of human infections do not result in death, but instead cause pathology in the
distal GI tract, similar to the murine model of infection. Therefore, this model serves to help
investigate whether GT activity was necessary for clinically relevant measures of TcdB-induced
pathogenesis in vivo.
In this established model, pretreatment with an antibiotic cocktail followed by a single dose
of clindamycin was used to disrupt the GI microbiome, creating a GI state permissive to C. dif-
ficile colonization (Fig 2A) [23]. Mice were then challenged with approximately 108 colony-
forming units (CFUs) of either wild-type C. difficile 630Δerm (WT), the tcdA-deletion mutant
C. difficile 630Δerm (ΔtcdA) or the GT-defective strain C. difficile 630Δerm GTD::D270N
(TcdB-GTD). C. difficile burdens per inoculum, with mean averages of 3.8 × 108 for WT,
3.7 × 108 for ΔtcdA, and 6.6 × 108 TcdB-GTD, did not statistically significantly differ between
the three strains (Fig 2B). To determine whether mutant strains were able to colonize in vivo,
mice were monitored for 5 days post infection with daily CFU counts from fecal samples.
Selective culturing confirmed that each mouse in all three groups shed detectable CFUs on at
least one day. Genomic DNA isolated from one fecal sample per cage was amplified to identify
the desired strain (S1A–S1C Fig). These data confirm that each group was colonized with the
administered strain.
Aggregate daily CFUs within each group displayed a wide range, with multiple measure-
ments falling below the limit of detection of 2 × 104 CFU/mL feces (Fig 2C). However, statisti-
cal analysis between shed CFUs of WT, ΔtcdA, and TcdB-GTD on days one to four were not
significantly different (Fig 2C), indicating similar levels of colonization among the three
groups over these days. We noted that on day five, C. difficile burdens were all below the limit
of detection in the TcdB-GTD group, which was significantly less compared to WT
(p = 0.0034) and narrowly missing significance as compared to the ΔtcdA group (p = 0.0538).
While this could suggest that the TcdB-GTD mutant displays different colonization kinetics
than the WT and ΔtcdA strains, we posit that the variance in these data are likely ascribed to a
systematic technical error or the high limit of detection of the method (2 × 104 CFU/mL). Not-
withstanding the potential differences in colonization kinetics, these data show that all strains
colonized in vivo.
Having established that all groups were colonized, we asked whether GT activity was
required for evidence of pathogenesis in the distal GI tract. Mice were sacrificed on day 5 post
infection to harvest caecal tissue for histological analysis. H&E-stained slides of caecal samples
were analysed for evidence of inflammatory cell infiltrates, mucosal hypertrophy, epithelial
disruption and submucosal edema, with a maximal severity score of 12 (Fig 2D). WT and
ΔtcdA groups displayed significant evidence of CDI. As compared to uninfected controls (Fig
2E), representative images of the WT and ΔtcdA groups display apoptotic cell sloughage (Fig
2F and 2G black arrows) and submucosal edema (Fig 2F and 2G black bar with asterisk).
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Histopathological scores were not significantly different between the WT and ΔtcdA groups
(p = 0.6537). Thus, the absence of TcdA does not significantly alter disease severity, consistent
with prior studies [4, 5]. In contrast, the TcdB-GTD group displayed significantly attenuated
pathology, with scores significantly lower than WT (p<0.0001) and ΔtcdA (p = 0.0002), and
lacking evidence of severe disease in representative images (Fig 2H). Further, pathology in the
TcdB-GTD group was not significantly different than uninfected controls (p = 0.0957). Taken
together, these data confirm that GT activity is required for pathogenesis in a clinically relevant
model of CDI.
Glucosyltransferase activity is required for C. difficile pathogenesis in a
hamster model
Having established that GT activity is required for pathogenesis in a non-lethal model of CDI,
we next asked whether the TcdB-GTD mutant strain was capable of inducing virulence in a
more sensitive animal model. To test this, we used the well-established hamster model of infec-
tion. Unlike the non-lethal mouse model of CDI, hamsters are exquisitely sensitive to C. diffi-
cile and uniformly succumb to fulminant infection when challenged with C. difficile expressing
wild-type toxin, but survive when challenged with avirulent strains [4]. As a consequence, we
reasoned that the hamster model could potentially reveal any symptoms of CDI which were
not detected in the less sensitive murine model.
To this end, pre-conditioned Syrian Golden hamsters were infected with approximately
10,000 heat-resistant colony-forming units (HR-CFU) of either WT, ΔtcdA or TcdB-GTD.
The uninfected control group was given sterile diluent at time-point 0. Ten animals were used
per infection group or control. Hamsters were monitored at regular intervals for primary
symptoms of CDI (severe wet tail, diarrhea, hypothermia, lying prone or unresponsive) and
were euthanized at the onset of fulminant CDI or at the 240th hour post infection. Five animals
infected with wild-type 630Δerm were symptomatic of fulminant CDI 36h following spore
administration (Fig 3A). The remaining hamsters in this group reached this stage by the 96h
time-point. The mean time to end-point following spore administration was 52h for the WT
group (Fig 3B). Similarly, animals infected with the ΔtcdA strain reached fulminant CDI with
an average time to end-point of 58h (Fig 3B). All animals in WT and ΔtcdA groups succumbed
to fulminant infection by 96h (Fig 3A and 3B). Deletion of tcdA did not significantly reduce
the time from spore administration to end point (P = 0.94), thus further supporting the cen-
trality of TcdB to disease pathogenesis. Hamsters in both the WT and ΔtcdA groups lost signif-
icant weight, up to 12.5% relative to their starting weights (Fig 3C). Meanwhile, none of the
subjects infected with the TcdB-GTD strain presented with any primary symptom of CDI
Fig 2. The GTD is required for typhlitis in murine infection. a) Schematic of non-lethal mouse model of CDI. Swiss Webster mice, excluding those
in the uninfected control group, were pretreated with an antibiotic cocktail in drinking water for three days (gray box, days -6 to -3), then orally
dosed with 1 mg clindamycin on day -1 to induce dysbiosis. On day 0, mice were orally challenged with C. difficile 630Δerm (wild-type, n = 7), C.
difficile 630ΔermΔtcdA (tcdA deletion mutant, n = 7), C. difficile 630ΔermΔtcdA GTD::D270N (GT-defective mutant, n = 7) or sterile PBS for the
uninfected control group (n = 3). Fecal pellets were collected daily to analyze C. difficile burden and caeca were harvested on day 5 for histological
analysis. b) C. difficile burden per 200 μL inoculum quantified for each bacterial strain. Statistical analysis between C. difficile strains was analyzed
using one-way ANOVA with Tukey’s multiple comparison test (ns, non-significant). c) Daily C. difficile burden measured from selective culture of
fecal samples. Graph displays each replicate with connecting line indicating the mean per group at each time point. Statistical analysis between groups
was performed on each day for days 1–4 via Kruskal-Wallis test (ns, non-significant) and on day 5 via Kruskal-Wallis with multiple comparisons
(��p<0.01 between wild-type and GT-defective mutant, all other comparisons non-significant). d) Histopathological score for combined
inflammatory cell infiltrates (0–3), mucosal hypertrophy (0–3), epithelial disruption (0–3) and submucosal edema (0–3), with each pathological
feature scored from normal (0) to severe (3) on H&E-stained caecal slides. Statistical analysis performed via one-way ANOVA with Tukey’s multiple
comparison test (ns, non-significant; ���p<0.001, ����p<0.0001). Representative H&E image of caecal section from e) uninfected control group, f)
wild-type group, g) tcdA deletion mutant group, and h) GT-defective mutant group. Images were taken with x20 magnification, and scale bar
indicates 100 μM. Black arrows indicate apoptotic cell sloughage, black bar with asterisk indicates submucosal edema.
https://doi.org/10.1371/journal.ppat.1008852.g002
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during the 240h infection period. Consequently, all subjects in this group were euthanized at
the 240h time-point (Fig 3A and 3B). Contrary to the results seen for the WT and ΔtcdA ani-
mals, subjects within this group gained up to 8% body weight relative to their starting weight
(Fig 3C). Terminal colonization was assessed as described in Materials and Methods. Each
infection group was colonized by C. difficile (S2 Fig). The approximately 2-log decrease
observed between the 24-96h samples for the WT and ΔtcdA groups compared with the 240h
GT-defective group, are in-line with previous 10-day colonization experiments [24]. Owing to
the sampling procurement adopted, it is not possible for us to demonstrate that each mutant
colonized the hamsters to the same extent. However, the NGS data assures us that the GT-
defective mutant was devoid of unintended mutations which may have affected colonization.
Taken together, these data indicate that the GTD is essential for the development of primary
symptoms during CDI.
Having established that the GTD is required for the onset of primary symptoms for CDI,
we next tested for any signs of inflammation induced by each respective mutant through histo-
pathological analysis of hamster caeca. Both the WT and ΔtcdA groups showed significant
signs of caecal inflammation yielding similar inflammation scores of approximately 5 based on
the sum of edema, neutrophil infiltration and tissue damage, with a maximum score of 9 per
animal subject (Fig 3D, 3F and 3G). On the contrary, the subjects in the uninfected control
group and the TcdB-GTD groups showed no symptoms of inflammation yielding a score of
zero for each individual subject (Fig 2D, 2E and 2H). The results from the histopathological
analysis corroborate those of the primary infection study thus suggesting that the GTD is
required for virulence in TcdB-induced CDI.
Concluding remarks
The data presented herein, in two well-established animal models of CDI, demonstrate that
GT activity is essential for in vivo C. difficile disease pathogenesis. Although recombinant GT-
defective TcdB is clearly capable of inducing cellular toxicity in vitro at higher nanomolar con-
centrations through both necrotic or pyknotic mechanisms [13, 15], the lack of any overt dis-
ease pathology for the GT-defective TcdB strain in either model tested here, suggests that the
absolute amounts of toxin needed to induce these cellular phenotypes may not be reached dur-
ing an infection in vivo. Future studies on the role of GT activity in other models and other
aspects of disease such as recurrence and colonization kinetics are warranted to determine
whether GT-independent effects play a role in other aspects of CDI.
Finally, the results presented here have important implications on our understanding of
CDI disease pathogenesis and obvious consequences for the design of novel SMIs aiming to
neutralize the toxic effects of TcdB as an alternative to antibiotic therapy. Before the discovery
of the necrotic and pyknotic mechanisms of toxicity, the major focus for SMI development
Fig 3. The GTD of TcdB is indispensable for in vivo pathogenesis in hamsters. a) Survival plot of Syrian Golden hamsters infected with
approximately 10,000 spores of C. difficile 630Δerm (wild-type, black lines), C. difficile 630ΔermΔtcdA (tcdA deletion mutant, red lines), C. difficile
630ΔermΔtcdA GTD::D270N (GT-defective mutant, blue lines) or sterile PBS for the uninfected control group (grey lines) (n = 10). Hamsters
were monitored for a period of 240h for primary symptoms of CDI. Animals were euthanized at the onset of fulminant infection, or at the 240h
time-point in the absence of considerable symptoms. Statistical significance between test groups and the uninfected control group was shown
according to the Peto log-rank test (p = ���� <0.0001) b) Time from inoculation to experimental endpoint. Statistical significance between test
groups and the uninfected control group according to one-way ANOVA followed by Dunnet’s multiple comparison test (p = ���� 0.001) c) Body
weight of each animal subject, relative to starting weight. Data points represent the mean ±SEM of 10 animal subjects per infection or control
group d) Terminal inflammation score for combined edema (0–3), tissue damage (0–3) and neutrophil infiltration (0–3) (maximum score of 9) as
assessed by histopathological analysis of H&E stained caeca. Statistical significance between test group and the uninfected control group according
to one-way ANOVA followed by Dunnet’s multiple comparison test (p = ���� 0.0001). Representative transverse cross-section of H&E stained
hamster caeca for e) Uninfected control group f) C. difficile 630Δerm (wild-type group) g) C. difficile 630ΔermΔtcdA (tcdA deletion group) h) C.
difficile 630ΔermΔtcdA GTD::D270N (GT-defective group). Scale bars represent the μM range.
https://doi.org/10.1371/journal.ppat.1008852.g003
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was focused on identification of GTD-targeted SMIs. Our demonstration that the GTD is
essential for the development of symptoms during CDI, reoffers the GTD as a well-validated
target for SMI development.
Materials & methods
Ethics statement
All murine experiments were carried out in accordance with APLAC protocols approved by
the Stanford University Institutional Care and Use Committee (IACUC).
Bacterial growth conditions
For strain development and in vitro analyses, C. difficile was routinely maintained on Brain
heart infusion medium (Oxoid) supplemented with 5μg/ml yeast extract, 0.1% w/v L-cysteine
(BHIS), C. difficile selective supplement comprising 250μg/ml D-cycloserine, and 8 μg/ml cefox-
itin (Oxoid) (BHIS CC), and where necessary, an additional supplementation of 15 μg/ml
thiamphenicol (BHIS CCTM). C. difficile cultures were grown at 37˚C in an anaerobic worksta-
tion (Don Whitley) with an anaerobic gas mixture comprising 80% N2, 10% H2 and 10% CO2.
For murine experiments, frozen stocks of wild-type and mutant strains were cultured on
CDMN agar plates (C. difficile agar base (Oxoid) supplemented with 7% (v/v) defibrinated
horse blood (Lampire Biological Laboratories), 32 mg/L moxalactam (Santa Cruz Biotechnol-
ogy), 12 mg/L norfloxacin (Sigma-Aldrich) and 500 mg/L cysteine hydrochloride (Fischer) in
an anaerobic chamber [27] at 37˚C for 24 hours. Single colonies were picked and grown anaer-
obically for 16–18 hours at 37˚C to saturation in 5 mL of pre-reduced reinforced Clostridial
medium (RCM, Oxoid) for inoculation.
For hamster experiments, strains were cultured on blood agar for 5d in order to generate
the spore stocks. Terminal colonization was assessed using C. difficile selective agar (Oxoid).
In both instances, strains were maintained in an anaerobic workstation, as described above.
Mutant generation
Strains and primers used in this study are listed in Tables 1 and S1 respectively. An in-frame
deletion mutant of tcdA in 630ΔermΔpyrE was generated using allelic-exchange technology
[20]. Left and right homology arms annealing up and downstream of tcdA were amplified by
PCR with primer sets tcdA LAF/LAR and RAF/RAR respectively. The fragments were spliced
together by splicing by overlap extension (SOEing) PCR and were subsequently cloned into
pMTL-YN3 [20], by means of their flanking SbfI and AscI restriction sites. The Knockout cas-
sette [28] was conjugated into 630ΔermΔpyrE exactly as described previously [21]. Transcon-
jugants were selected on the basis of thiamphenicol resistance on BHIS CCTM plates. Single
cross-over integrants were identified following sub-culturing onto BHIS CCTM by PCR using
two primer sets to screen for integration at the left or right homology arms: tcdA diag F/YN3 R
and YN3 F/ tcdA diag R; each containing a primer annealing to the chromosome and a primer
annealing to the KOC plasmid. Confirmed single cross-over clones were grown on non-selec-
tive BHIS medium and thereafter C. difficile minimal medium [29] containing 500μg/ml
5-fluoroorotic acid (FOA) and 1μg/ml uracil to force plasmid loss through the counter-selec-
tion marker pyrE, and to select for double cross-over mutants before confirming plasmid loss
on the basis of thiamphenicol sensitivity. The desired deletion mutants were identified by PCR
amplification of the tcdA locus using the diagnostic primers tcdA diag F and tcdA diag R. An
additional PCR was conducted on putative mutants with internal primers annealing within
tcdA to ensure the absence of contaminating wild-type sub-populations.
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For the generation of a GTD-defective mutant, two circa 1kb fragments were amplified by
two PCR reactions for each target, comprising a forward and reverse primer containing SbfI
and AscI restriction sites respectively, paired with internal mutagenic primers encompassing
the desired nucleotide substitutions. The mutagenic forward primer GTD mut F, contained
the exact reverse complemented sequence of the mutagenic reverse primer, GTD mut R to
facilitate subsequent SOEing of the two fragments. Spliced products were then cloned into
pMTL-YN3 as described above to generate a substitution cassette (SC) for GTD D270N. The
procedure hereafter mimicked that described above for the chromosomal deletion, however,
owing to the desired mutagenesis being a substitution rather than a deletion, putative mutants
were assessed by PCR followed by Sanger sequencing of the amplicon. The read for each clone
was aligned to the wild-type reference sequence and the desired substitution sequence to con-
firm the presence or absence of the desired codon substitution. The pyrE locus of each strain
was then restored exactly as described previously [21].
Whole genome sequencing
Genomic DNA was extracted from both mutant strains and the wild-type parental and sent for
next generation sequencing (NGS) using the Illumina MiSeq platform at MicrobesNG (Uni-
versity of Birmingham, UK). The paired reads were trimmed and mapped to the reference
genome sequence for C. difficile 630 (Accession: AM180355. Thereafter, each strain was ana-
lyzed for any single nucleotide variations (SNVs), insertions or deletions of DNA compared
with the reference genome sequence, using CLC Genomics Workbench software (Qiagen,
Netherlands). Sequencing reads were deposited to the NCBI Sequencing Read Archive under
accession number PRJNA623295.
Western blot detection of C. difficile toxins
Secreted TcdA and TcdB was detected by Western blot on 40x trichloracetic acid protein con-
centrates derived from 48h sterile-filtered supernatants exactly as described previously [21]
using HRP-Chicken anti-Clostridium difficile Toxin A IgY and anti-Clostridium difficile Toxin
B IgY antibodies (Gallus-Immunotech, USA) respectively.
Table 1. Strains used in this study.
Strain/Plasmid Description Origin
Strain
E. coli
Top 10 Cloning host Invitrogen
CA434 Conjugation host [25]
C. difficile
630Δerm Erythromycin sensitive clone of CD630 [26]
630ΔermΔpyrE pyrE mutant to facilitate AE mutagenesis [20]
630ΔermΔpyrEΔtcdA Initial tcdA-deletion mutant This study
630ΔermΔtcdA pyrE-restored tcdA-deletion mutant This study
630ΔermΔpyrEΔtcdA.TcdB::GTD D270N Initial GTD-defective mutant This study
630ΔermΔtcdA.TcdB::GTD D270N pyrE-restored GTD-defective mutant This study
Plasmid
pMTL-YN3 Knockout vector for 630Δerm [20]
pMTL-YN3-tcdA KOC As above with knockout cassette for tcdA This study
pMTL-YN3-TcdB::GTD D270N SC As above with substitution cassette for TcdB::GTD D270N This study
pMTL-YN1 pyrE-restoration vector for 630Δerm [20]
https://doi.org/10.1371/journal.ppat.1008852.t001
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Automated growth curve
Growth profiles of the wild-type parental and mutant strains were assessed by automated
growth curve using a Promega Glomax plate reader (Promega, USA) exactly as described pre-
viously [30].
Murine model of infection
Age- and sex-matched male and female conventional Swiss Webster mice (SWEF, Taconic,
bred in-house) ages 8–12 weeks were fed standard chow and had an average starting weight of
38 g. Mice were randomly divided into four groups: uninfected controls without antibiotic
pre-treatment (n = 3), or infected with WT (n = 7), ΔtcdA (n = 7) or TcdB-GTD (n = 7). Mice,
excluding those in the control group, were pre-treated with an antibiotic cocktail (kanamycin
(0.4 mg/mL), gentamycin (0.035 mg/mL), colistin (850 U/mL), metronidazole (0.215 mg/mL)
and vancomycin (0.045 mg/mL)) in drinking water for 3 days, starting 6 days before inocula-
tion, as previously reported [23]. Mice were switched to regular water for 2 days, and then
orally administered 1 mg of clindamycin on day -1 (excluding those in the uninfected control
group). On day 0, experimental WT, ΔtcdA and TcdB-GTD were orally challenged with
approximately 108 CFU (in 200 μL RCM) of the appropriate wild-type or mutant strain from
overnight culture. Mice were monitored with daily weights, and fecal samples were collected
for 5 days to measure daily C. difficile CFU burden. Mice were then sacrificed according to the
guidelines on human termination on experimental day 5 after C. difficile challenge. Caecal tis-
sues were collected for histological analysis. Genomic DNA from fecal samples from one
mouse per cage was amplified to ensure colonization with the appropriate strain, using a pro-
tocol adapted from [31, 32]. Briefly, 10–30 mg fecal sample was resuspended in 500–700 μL
TRIS-buffered saline (TBS, 50 mM TRIS, 150 mM NaCl, pH 7.4) and disrupted with 0.1 mm
glass beads using Mini-BeadBeater-96 (Biospec Products) for 3 minutes. Genomic DNA was
extracted from the supernatant with two rounds of phenol:chloroform:isoamyl alcohol
(25:24:1) in a 1:1 ratio with supernatant, then ethanol precipitation was performed. The result-
ing DNA pellet was resuspended in 200 μL PBS and purified of PCR inhibitors using a
QIAamp DNA blood Mini kit (Qiagen) before amplifying the regions of interest using tcdA
int F and R primers (TcdA internal region) and GTD diag F and R primers (GTD-encoding
region of TcdB).
Fecal and Inoculum and CFU quantification in the murine model
Fecal samples were collected from mice directly into Eppendorf tubes and placed on ice. To
measure C. difficle CFU burdens, 1 μL feces was resuspended in 200 μL sterile PBS. Samples
were then serially diluted 10-fold into PBS, with 10 μL struck onto CDMN plates in duplicate.
Plates were incubated anaerobically at for 16–24 hours at 37˚C before quantification. To enu-
merate inoculum CFUs, 200 μL of each strain was used as starting material, with serial dilution
and plating as above.
Histopathological assessment of murine samples
Proximal colon and caecal sections were collected and fixed in 10% neutral buffered formalin,
processed (Leica), paraffin embedded (Leica), sectioned at 5 μm, mounted on glass slides and
H&E stained (HistoTec Laboratory). Sections were scored by a veterinary pathologist blinded
to the identity of the samples (Dr. Donna M. Bouley, Stanford University Department of Com-
parative Medicine) using a scoring system adapted from Pawlowski et al [33]. Caecal sections
were assessed for inflammatory cell infiltrates (0–3), mucosal hypertrophy (0–3), epithelial
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disruption (0–3) and submucosal edema (0–3) for a maximal score of 12, with each pathologi-
cal feature scored from normal (0) to severe (3). Images representative of each treatment
group are shown in Fig 2.
Hamster model of infection
Animal studies were planned and performed according to the ARRIVE guidelines [34] under
license by Evotec Ltd, UK. Adult male Syrian Golden hamsters weighing between 82-111g
were pre-conditioned with 30mg/kg clindamycin to disrupt their gut microbiota for a period
of 5d. Hamsters were then randomly divided into four groups: uninfected controls (n = 10), or
infected with WT (n = 10), ΔtcdA (n = 10) or TcdB-GTD (n = 10). Subjects in each experimen-
tal group were administered with approximately 10,000 spores (heat-resistant colony forming
units, HR-CFU) of the appropriate wild-type or mutant strain or sterile PBS (uninfected con-
trol group). Animals were monitored daily for symptoms of CDI for a period of 240h. Animals
were euthanized by pentobarbitone overdose, if they were deemed to be symptomatic of fulmi-
nant CDI. Criteria for fulminant CDI were: hypothermia <34˚C, 20% weight loss, severe diar-
rhea, inability to reach food and water or severely hunched posture with piloerection.
Euthanized subjects were dissected and terminal-colonization was determined in-house at the
animal research facility using fecal samples plated on C. difficile selective medium (Oxoid,
USA). The presence of C. difficile was confirmed using the C. difficile latex agglutination kit
(Oxoid, USA). To confirm the identity of the isolates, HR-CFU were isolated from caecum,
small intestine and colon samples in the research facility. Presumptive isolates were confirmed
by colony PCR for tcdA flanking region, tcdA internal region and GTD-encoding region of
tcdB. Hamster caeca were fixed in 10% buffered neutral formalin (BNF) and stored until histo-
pathological assessment.
Histopathological assessment of hamster caeca
Fixed transverse cross-sections of hamster caeca were routinely processed for paraffin embed-
ding, sectioned at 5 μm, mounted on glass slides, and H&E stained. Thereafter a trained
pathologist individually scored each sample for edema (1–3), neutrophil infiltration (1–3) and
tissue damage (1–3), with a maximum potential score of 9 per animal subject.
Statistical analysis
Statistical analyses (one-way ANOVA with Tukey’s or Dunnet’s multiple comparison test,
Kruskall-Wallis test with multiple comparisons, as indicated in figure legends) were performed
using the GraphPad Prism 7 and 8 software (GraphPad Software).
Supporting information
S1 Table. Oligonucleotide primers used in this study.
(PDF)
S1 Fig. Genomic isolation and PCR confirms appropriate strains from feacal samples in
mouse model of CDI. a) Gel image following genomic isolation of DNA from fecal samples
and PCR of the tcdA gene using the internal primers tcdA int F/tcdA int R. The absence of a
500bp product indicates ΔtcdA isolate. b) Gel image following genomic isolation of DNA from
fecal samples and PCR of the GTD of tcdB using GTD diag F/R primers. Strain labels: C. diffi-
cile 630Δerm (wild-type) cages 1 and 2; C. difficile 630ΔermΔtcdA (ΔtcdA) cages 1 and 2; C. dif-
ficile 630ΔermΔtcdA GTD::D270N (ΔtcdA TcdB-GTD) cages 1 and 2. c) Sequence alignment
of the GTD region of tcdB for C. difficile 630ΔermΔtcdA GTD::D270N with the wild-type
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reference sequence of 630Δerm. The gac-aat substitution is highlighted in a red box.
(PDF)
S2 Fig. Hamster subjects are sufficiently colonized by C. difficile. Terminal burden (heat-
resistant colony-forming units/g HR-CFU/g) of C. difficile for uninfected, WT, ΔtcdA and
TcdB-GTD infection groups. Spores were isolated from fecal samples at the day of experimen-
tal end-point for each animal subject. Since the burden was determined at different time-
points for each animal subject, it is not appropriate to perform statistical analyses for these
data.
(PDF)
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